Prolaio

Prolaio

Decentralized cardiovascular trials with wearables

Product Manager - Clinical Endpoints

Full-TimePosted on 6/26/2026
$159k/yr

+ Bonus + Equity

Senior
Chicago, IL, USA
In Person

About the job

Requirements
  • 8+ years in product management, clinical science, or endpoint/measurement roles in Digital Health, MedTech, or Life Sciences
  • Deep familiarity with clinical trial endpoints across modalities—digital measures, wearable and sensor data, lab-based biomarkers, and ePRO/eCOA
  • Hands-on experience taking a measure or biomarker from concept through fit-for-purpose validation
  • Working knowledge of the regulatory bar for endpoints (FDA/EMA, biomarker qualification, validation frameworks such as DiMe V3)
  • Excellent communication skills, with a knack for turning scientific and regulatory rigor into clear product decisions
Responsibilities
  • Own the full menu of clinical endpoints our platform offers sponsors—digital measures, lab-based biomarkers, ePRO/eCOA, and beyond. Decide what we build, what we buy, and what we partner for, anchored in real sponsor and therapeutic-area need.
  • Maintain a clear, prioritized endpoint roadmap, sequencing investments by clinical impact, sponsor demand, and feasibility.
  • Track the evolving endpoint landscape—new digital biomarkers, novel sensors, and shifting regulatory expectations—and translate it into where we place our bets.
  • Define what data we collect and from which medical devices and wearable sensors, weighing signal fidelity, patient burden, and fitness for the question at hand.
  • Evaluate and select sensor and device partners, setting the bar for data quality, interoperability, and regulatory readiness.
  • Define the raw data we capture and retain so that today’s collection supports tomorrow’s biomarkers and endpoints, not just the trial in front of us.
  • Partner with Data Science and Clinical to turn raw device and sensor signals into meaningful digital biomarkers, owning the use case, the target population, and the measure’s intended claim
  • Write clear requirements for new biomarkers and guide them from concept through prototype, pilot, and trial-ready measure.
  • Curate the wider endpoint set alongside digital biomarkers—lab-based biomarkers, ePRO/eCOA, and other functional assessments
  • Own the fit-for-purpose case for each endpoint, working with Clinical, Data Science, and Regulatory through verification, analytical validation, and clinical validation (e.g., the DiMe V3 framework).
  • Stay close to the regulatory bar for endpoints—FDA and EMA expectations, biomarker qualification pathways, and ePRO/eCOA standards—and build the evidence so our endpoints stand up to sponsor and agency scrutiny.
  • Translate dense scientific and regulatory requirements into clear, buildable specs for the teams developing and delivering each measure.
  • Work with the Chief Medical Officer (CMO) and Clinical to ensure every endpoint reflects clinical reality and answers a real question for cardiovascular trials.
  • Partner closely with the Product Manager for AI, Real-World Data & Advanced Analytics so the endpoints you define and the platform they build fit together cleanly—shared data, no duplicated effort, clear ownership.
  • Engage directly with trial sponsors to understand their endpoint needs and bring that voice back into the roadmap.
  • Collaborate with Quality and Regulatory to ensure data collection and endpoint delivery meet the standards expected in regulated trial environments (e.g., HIPAA, 21 CFR Part 11, GxP)

About the company

Prolaio builds cardiovascular clinical research infrastructure that turns homes into trial sites using medical-grade wearables to capture continuous real-world heart data. Its intelligence engine translates signals into clinically robust endpoints and FDA-cleared digital biomarkers. Sponsors use the platform for recruitment, 24/7 data capture, adaptive analytics, and dashboards, enabling fully managed real-world trials and post-discharge monitoring. The goal is to make cardiovascular trials faster, scalable, and more accurate by leveraging home data and standardized digital endpoints.

Company Size

51-200

Company Stage

Early VC

Total Funding

$25.5M

Headquarters

Scottsdale, Arizona

Founded

2022

Get referred to Prolaio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kardigan's August 11, 2026 results credit Prolaio for three late-stage programs, proving internal dependence.
  • Prolaio's FDA-cleared eVO2peak and AFib burden strengthen cardiovascular endpoint differentiation immediately.
  • New Prolaio strategy and customer-success roles in 2026 signal active commercialization, not shutdown.

What critics are saying

  • Kardigan controls Prolaio now, so standalone SaaS independence ended by September 2026.
  • Prolaio still shows customer-success hiring in 2026, signaling heavy services burden and margin pressure.
  • Competitors like Medable, ActiGraph, and Biofourmis sell broader decentralized-trial stacks and unbundle Prolaio's niche.

What makes Prolaio unique

  • Kardigan bought Prolaio on March 27, 2025, bundling data with therapeutics.
  • Prolaio runs FDA-cleared cardiovascular biomarkers from 4 million on-body hours across 26 countries.
  • Its platform converts home wearables into trial endpoints, dashboards, and structured regulatory data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Stock Options

Company Equity

Retirement Plan: 401(k) plan

Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-1%
Business Wire
Mar 28th, 2025
Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform

Kardigan, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired Prolaio, a clinical intelligence comp...

U.S. Securities and Exchange Commission
Sep 13th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

INACTIVE